Results 41 to 50 of about 8,545 (210)

Molnupiravir; an effective drug in treating COVID-19? [PDF]

, 2021
n/
Alireza Pouramini, Fatemeh Kafi, Hamid Reza Jahantigh, Sanam Saeifar, Shakiba Hassanzadeh   +4 more
core   +2 more sources

Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?

Therapeutic Advances in Drug Safety, 2022
Plain Language Summary Could natural plant pigment (chlorophyll) derivatives (chlorophyllins) improve the safety of the antiviral Molnupiravir, used to treat COVID-19 disease?
Nicole F. Clark, Andrew W. Taylor-Robinson, Kirsten Heimann   +2 more
doaj   +1 more source

Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation studyResearch in context

EClinicalMedicine, 2023
Summary: Background: Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for COVID-19 treatment, but direct comparisons of their effectiveness have been limited.
Eric Yuk Fai Wan, Vincent Ka Chun Yan, Zoey Cho Ting Wong, Celine Sze Ling Chui, Francisco Tsz Tsun Lai, Xue Li, Carlos King Ho Wong, Ivan Fan Ngai Hung, Chak Sing Lau, Ian Chi Kei Wong, Esther Wai Yin Chan   +10 more
doaj   +1 more source

SARS-CoV-2 infection in solid organ transplant recipients: Experience with molnupiravir [PDF]

, 2023
SARS-CoV-2 infection; Transplant recipients; Solid organInfecció per SARS-CoV-2; Receptors de trasplantament; Òrgans sòlidsInfección por SARS-CoV-2; Receptores de trasplantes; Órganos sólidosSolid organ transplant recipients (SOTR) constitute one of the ...
Len, Oscar, Villamarín Melio, Miguel
core   +1 more source

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system

Frontiers in Pharmacology, 2023
Molnupiravir, an urgently approved drug during the Coronavirus Disease 2019 (COVID-19) pandemic, serves as the basis for our study, which relies on the Food and Drug Administration Adverse Event Reporting System (FAERS).
Yankun Liang, Yankun Liang, Lin Ma, Yuting Wang, Jingping Zheng, Ling Su, Jun Lyu, Jun Lyu   +7 more
doaj   +1 more source

Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data [PDF]

, 2023
Concerns have been raised about the actual benefit and safety of molnupiravir, a new antiviral treatment for coronavirus disease 2019 (COVID-19). In order to provide additional evidence to support its use, we aimed to evaluate the real safety profile ...
Montanaro N., Motola D., Santi Laurini G.   +2 more
core   +1 more source

Earth-friendly-assessed silver-nanoparticles spectrophotometric method for rapid and sensitive analysis of Molnupiravir, an FDA-approved candidate for COVID-19: application on pharmaceutical formulation and dissolution test

BMC Chemistry, 2023
Molnupiravir is the first oral direct-acting antiviral prodrug recently approved for the COVID-19 pandemic. Here and for the first time, we present a novel, sensitive, robust, and simple silver-nanoparticles spectrophotometric technique for molnupiravir ...
Ahmed R. Mohamed, Ebrahim Abolmagd, Israa M. Nour, Mohamed Badrawy, Mohamed A. Hasan   +4 more
doaj   +1 more source

Equipoise, standard of care, and consent: Responding to the authorisation of new COVID-19 treatments in randomised controlled trials [PDF]

, 2022
In response to the COVID-19 pandemic, large-scale research and pharmaceutical regulatory processes have proceeded at a dramatically increased pace with new and effective, evidence-based COVID-19 interventions rapidly making their way into the clinic ...
Dal-Ré, Rafael, Holm, Søren, Lewis, Jonathan   +2 more
core   +4 more sources

Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model. [PDF]

, 2022
The recent emergence of the SARS-CoV-2 Omicron variant of concern (VOC) containing a heavily mutated spike protein capable of escaping preexisting immunity identifies a continued need for interventional measures.
Bohler, WF, Feldmann, F, Feldmann, H, Griffin, AJ, Jarvis, MA, Lewis, MC, Meade-White, K, Okumura, A, Rosenke, K, Rosenke, R, Shaia, C   +10 more
core   +2 more sources

Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents [PDF]

, 2022
BACKGROUND: The efficacy on the Omicron variant of the approved early- coronavirus disease 2019 (COVID-19) therapies, especially monoclonal antibodies, has been challenged by in vitro neutralization data, while data on in vivo antiviral activity are ...
Alessandra, Vergori, Alessandro, Cozzi Lepri, Andrea, Antinori, AnnaRosa, Garbuglia, Claudia, Cimaglia, Eleonora, Lalle, Emanuela, Caraffa, Emanuele, Nicastri, Enrico, Girardi, Eugenia, Milozzi, Fabrizio, Carletti, Fabrizio, Maggi, Francesca, Colavita, Francesco, Vaia, Gaetano, Maffongelli, Ilaria, Mastrorosa, INMI COVID-19 Outpatient Treatment Study Group, Jessica, Paulicelli, Lavinia, Fabeni, Pierluca, Piselli, Raffaella, Libertone, Serena, Vita, Silvia, Rosati, Simone, Lanini, Valentina, Mazzotta   +24 more
core   +2 more sources